Allergan Inc. is a technology driven global health care company headquarterd in Irvine, California. It is a worldwide provider of eye care and speciality pharmaceutical products. Allergan develops and commercialises products in the:

• eye care pharmaceutical
  
• ophthalmic surgical device
  
• over-the-counter contact lens care
  
• movement disorder
  
• dermatological markets that deliver value, satisfy unmet needs and improve patients' lives

Allergan targets its products and R&D to specific disease areas. These include glaucoma and retinal disease, cataracts, dry eye, psoriasis, acne, photodamage, movement disorders, pain, metabolic disease and various types of cancer.

The company has established leadership positions in leading-edge technologies such as second-generation alpha2 agonist compounds, receptor-selective retinoids, foldable intraocular lenses (IOLs), injectable neurotoxin and convenient contact lens care products.

Allergan markets products in more than 100 countries. In 1998, sales outside the United States generated approximately 54% of the Company's $1.25 billion worldwide revenue. Founded in 1948, Allergan became a public company in 1970, merged with SmithKline Beckman in 1980, and was re-established as an independent entity in 1989.